Literature DB >> 16723269

Dopamine agonist therapy for Parkinson disease and pathological gambling.

Akiko Imamura1, Ryan J Uitti, Zbigniew K Wszolek.   

Abstract

We report 6 patients with pathological gambling during pharmacologic treatment for Parkinson disease (PD). Four patients were treated with levodopa/carbidopa and dopamine agonist (DA), and 2 patients received DA monotherapy. We reviewed several published reports regarding pathological gambling and antiparkinsonian therapy and suggest that more advanced PD and antiparkinsonian combination therapy (e.g., levodopa/carbidopa and DA) increases the risk for development of pathological gambling behavior compared with monotherapy with either DA or levodopa/carbidopa.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723269     DOI: 10.1016/j.parkreldis.2006.02.004

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  7 in total

1.  Testing an Incentive-Sensitisation Approach to Understanding Problem Slot-Machine Gambling Using an Online Slot-Machine Simulation.

Authors:  Belinda Davey; Robert Cummins
Journal:  J Gambl Stud       Date:  2018-09

Review 2.  Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention.

Authors:  Angelo Antonini; Roberto Cilia
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  Management of impulse control disorders in Parkinson's disease.

Authors:  Wendy R Galpern; Mark Stacy
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

Review 4.  Current status of symptomatic medical therapy in Parkinson's disease.

Authors:  Stewart A Factor
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

5.  Study protocol: the JEU cohort study--transversal multiaxial evaluation and 5-year follow-up of a cohort of French gamblers.

Authors:  Gaëlle Challet-Bouju; Jean-Benoit Hardouin; Jean-Luc Vénisse; Lucia Romo; Marc Valleur; David Magalon; Mélina Fatséas; Isabelle Chéreau-Boudet; Mohamed-Ali Gorsane; Marie Grall-Bronnec
Journal:  BMC Psychiatry       Date:  2014-08-20       Impact factor: 3.630

6.  Assaying the effect of levodopa on the evaluation of risk in healthy humans.

Authors:  Mkael Symmonds; Nicholas D Wright; Elizabeth Fagan; Raymond J Dolan
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

Review 7.  Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review.

Authors:  Marie Grall-Bronnec; Anne Sauvaget; Fanny Perrouin; Juliette Leboucher; François Etcheverrigaray; Gaëlle Challet-Bouju; Louise Gaboriau; Pascal Derkinderen; Pascale Jolliet; Caroline Victorri-Vigneau
Journal:  J Clin Psychopharmacol       Date:  2016-02       Impact factor: 3.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.